Systematic screening allows reduction of adverse antiepileptic drug effects - A randomized trial

被引:269
作者
Gilliam, FG
Fessler, AJ
Baker, G
Vahle, V
Carter, J
Attarian, H
机构
[1] Washington Univ, Dept Neurol, Epilepsy Program, St Louis, MO 63110 USA
[2] Univ Dept Neurosci, Liverpool, Merseyside, England
关键词
D O I
10.1212/WNL.62.1.23
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To determine the effectiveness of systematic screening with a brief 19-item self-report instrument, the Adverse Events Profile (AEP), to reduce adverse effects of antiepileptic drugs (AEDs) and improve subjective health status. Methods: The authors performed a prospective randomized trial comparing the use of the AEP with usual care without the AEP. Sixty-two patients with an AEP score of greater than or equal to45 were enrolled from a consecutive group of 200 consenting adults with epilepsy. Results: The mean percent improvement in AEP scores was greater in the patient group for which clinicians received the AEP compared with the usual care group (25% vs 5%; p<0.01). Mean change in Quality of Life in Epilepsy Inventory (QOLIE)-89 total scores was not different between groups, but for the entire sample QOLIE-89 change was greater for patients having a 15-point improvement in AEP scores than for those with a 0- to 15-point improvement or a worsened score (24 vs 12 vs 3; analysis of variance, p<0.008). More patients in the AEP group had a >15-point improvement in QOLIE-89 score (p<0.03). Use of the AEP was associated with a 2.8-fold increase (95% CI, 1.7 to 4.8) in AED modifications. No difference in seizure rates was observed. Conclusions: Systematic screening for antiepileptic drug side effects may increase identification of toxicity and guide medication changes to reduce adverse effects and possibly improve subjective health status.
引用
收藏
页码:23 / 27
页数:5
相关论文
共 16 条
[1]  
[Anonymous], 1981, Epilepsia, V22, P489
[2]   DEVELOPMENT OF A NOVEL SCALE TO ASSESS LIFE FULFILLMENT AS PART OF THE FURTHER REFINEMENT OF A QUALITY-OF-LIFE MODEL FOR EPILEPSY [J].
BAKER, GA ;
JACOBY, A ;
SMITH, DF ;
DEWEY, ME ;
CHADWICK, W .
EPILEPSIA, 1994, 35 (03) :591-596
[3]   Quality of life of people with epilepsy: A European study [J].
Baker, GA ;
Jacoby, A ;
Buck, D ;
Stalgis, C ;
Monnet, D .
EPILEPSIA, 1997, 38 (03) :353-362
[4]   Commission on outcome measurement in epilepsy, 1994-1997: Final report [J].
Baker, GA ;
Camfield, C ;
Camfield, P ;
Cramer, JA ;
Elger, CE ;
Johnson, AL ;
da Silva, AM ;
Meinardi, H ;
Munari, C ;
Perucca, E ;
Thorbecke, R .
EPILEPSIA, 1998, 39 (02) :213-231
[5]  
*CDC, 2000, NAT AMB MED CAR SURV
[6]   Health care policy - Outcomes research: Measuring the end results of health care [J].
Clancy, CM ;
Eisenberg, JM .
SCIENCE, 1998, 282 (5387) :245-246
[7]   New antiepileptic drugs: Comparison of key clinical trials [J].
Cramer, JA ;
Fisher, R ;
Ben-Menachem, E ;
French, J ;
Mattson, RH .
EPILEPSIA, 1999, 40 (05) :590-600
[8]   DEVELOPMENT OF THE QUALITY-OF-LIFE IN EPILEPSY INVENTORY [J].
DEVINSKY, O ;
VICKREY, BG ;
CRAMER, J ;
PERRINE, K ;
HERMANN, B ;
MEADOR, K ;
HAYS, RD .
EPILEPSIA, 1995, 36 (11) :1089-1104
[9]   Use of the QOLIE-31 in routine clinical practice [J].
Grudzinski, AN ;
Hakim, Z ;
Coons, SJ ;
Labiner, DM .
JOURNAL OF EPILEPSY, 1998, 11 (01) :34-47
[10]   PHENOBARBITONE, PHENYTOIN, CARBAMAZEPINE, OR SODIUM VALPROATE FOR NEWLY-DIAGNOSED ADULT EPILEPSY - A RANDOMIZED COMPARATIVE MONOTHERAPY TRIAL [J].
HELLER, AJ ;
CHESTERMAN, P ;
ELWES, RDC ;
CRAWFORD, P ;
CHADWICK, D ;
JOHNSON, AL ;
REYNOLDS, EH .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1995, 58 (01) :44-50